Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference Accessibility StatementSkip Navigation HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of l ...

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update Accessibility StatementSkip NavigationConference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provid ...

Volition Announces Detection of Over 95% of Early-Stage Cancers Accessibility StatementSkip Navigation HENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of cancer, including early stage cancer using its breakthrough Capture- Seqâ"¢ technology. Dr. Jake Micallef, Chief Scientific Officer, Volition, commented: Volition Announce ...

VolitionRx Limited (VNRX) shares jumped 37.59 percent to $0.2628, gaining $0.0718 on Wednesday, after the company announced what it described as a scientific breakthrough in liquid biopsy . The stock is currently trading at $0.2628 compared with its previous close of $0.1900. Shares opened at $0.2889 and traded between $0.2524 and $0.3029 during the session on the New York Stock Exchange. Trading volume reached about 203.45 million shares, far above the average volume of about 2.02 million shares.Volition ...

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA Accessibility StatementSkip Navigation HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfD ...

Core Insights - VolitionRx Limited has announced the completion of validation for its automated Nu.Q® Vet Cancer Test in collaboration with Fujifilm Vet Systems, marking a significant advancement in veterinary diagnostics [1] - The automated test is expected to enhance efficiency in veterinary hospitals, with over 1,700 facilities in Japan already registered to use the test since its launch in July 2024 [1] - The partnership with Fujifilm Vet Systems presents a substantial revenue opportunity for Volition, given the large market of approximately seven million pet dogs in Japan [1] Company Overview - Volition is a multinational epigenetics company focused on developing blood tests for early disease detection, including cancer, with a commitment to improving outcomes for both humans and animals [1] - The company operates research and development activities primarily in Belgium, with additional offices in the U.S. and London [1] - Volition's technology platform demonstrates synergy between human and veterinary diagnostics, utilizing the same automated analyzer platform for both [1] Market Context - Cancer is identified as the leading cause of adult canine deaths, and early detection through the Nu.Q® Vet Cancer Test can significantly improve treatment outcomes [1] - Fujifilm Vet Systems, a subsidiary of Fujifilm Holdings Corporation, is a key player in the Japanese veterinary diagnostics market, providing services to approximately 11,000 veterinary medical facilities [1] - The automated testing capability is expected to meet the increasing demand for rapid and high-throughput diagnostic solutions in veterinary medicine [1]

Core Insights - VolitionRx Limited has made significant clinical and commercial progress, highlighting licensing momentum and advancements in various diagnostic technologies [1][2] Group 1: Licensing and Commercialization - The company is in active discussions with approximately 10 global diagnostic leaders for licensing agreements [1][2] - Anticipated announcements of additional agreements during 2026 as negotiations progress [2] Group 2: Clinical Developments - The Nu.Q® NETs assay is included in a $7.3 million government-backed DETECSEPS program in France for early sepsis detection [1] - A reimbursement submission for lung cancer testing in France is underway, with routine clinical use expected by Q4 2026 [1] - New clinical utility of the Nu.Q® NETs assay has been demonstrated for managing Hidradenitis Suppurativa, a disease affecting about 1% of the global population [1] Group 3: Market Opportunities - The Capture-Seq™ platform presents a $23 billion annualized opportunity in cancer detection [1][2] - The total addressable market for Nu.Q® NETs in sepsis and chronic conditions is estimated at $3.8 billion [2] - The Nu.Q® Vet (Canine/Feline) market is projected to exceed $1 billion, with the canine test already commercially available [2] Group 4: Veterinary Breakthroughs - The Nu.Q® Vet Feline assay achieved 100% specificity in detecting feline lymphoma, marking a significant advancement in veterinary diagnostics [1] - This breakthrough is expected to unlock a $5 million milestone payment upon publication in a peer-reviewed journal [1]

Core Insights - VolitionRx Limited has appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor for its Nu.Q® Discover assays in Japan, enhancing its market presence in the region [1] - The company serves nearly 100 clients globally, including major pharmaceutical and diagnostic firms, and anticipates continued revenue growth for Nu.Q® Discover in 2026 [1] - The Total Accessible Market for relevant companion diagnostics is estimated to be just under $1 billion, indicating significant growth potential [1] Company Developments - The collaboration with MBL is expected to generate interest and data for potential future regulatory applications for diagnostic status in Japan [1] - In 2025, Volition achieved several milestones, including a co-marketing agreement with Hologic Diagenode and the first commercial sale of its High Throughput Synthetic Sepsis method [1] - The Nu.Q® Discover program provides advanced assays for rapid epigenetic profiling, supporting drug developers and researchers in various therapeutic areas [1] Market Context - MBL, established in 1969, is a leading provider of clinical research tools in Japan, focusing on autoimmune diseases and genetic diagnostics [1] - The partnership aims to expand access to nucleosome-based biomarkers for drug developers and researchers, contributing to advancements in personalized medicine [1] - VolitionRx is dedicated to improving disease detection and monitoring through cost-effective blood tests, with a focus on cancers and diseases related to NETosis [1]

Core Viewpoint - VolitionRx Limited has received a notice of non-compliance from NYSE American regarding its continued listing standards due to insufficient stockholders' equity, requiring a plan to regain compliance by August 6, 2027 [1][2] Compliance Requirements - The company is not in compliance with Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide, which mandates stockholders' equity of at least $2.0 million, $4.0 million, and $6.0 million respectively, based on reported losses over recent fiscal years [1] - Volition must submit a compliance plan by March 8, 2026, detailing actions to regain compliance [1] Delisting Proceedings - If the plan is not submitted or accepted, or if compliance is not achieved by the deadline, NYSE American will initiate delisting proceedings [1] - The common stock will continue to trade under the symbol "VNRX" with an added designation of ".BC" indicating "below compliance" status [1] Business Operations - The notice does not impact the ongoing business operations or reporting requirements of the company with the U.S. Securities and Exchange Commission [1] - Volition is committed to regaining compliance and plans to submit a detailed plan to the NYSE American [1]

Core Viewpoint - VolitionRx Limited is sponsoring a symposium at the European Hidradenitis Suppurativa Foundation Conference to present findings on the Nu.Q NETs assay, which aids in the management of Hidradenitis Suppurativa (HS) through a precision medicine approach [1][2][3]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection and monitoring of diseases [11][12]. - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, aiming to enhance patient quality of life [12]. Industry Context - Hidradenitis Suppurativa (HS) is a chronic condition affecting approximately 1% of the global population, characterized by painful skin abscesses and scarring [3][9]. - The condition is difficult to manage, and the introduction of biological treatments has shown varied responses among patients, highlighting the need for a precision medicine approach [4][9]. Product and Market Potential - The Nu.Q NETs assay is CE-Marked for clinical use in 27 EU member states and is positioned as a simple, low-cost test to detect diseases associated with NETosis, with a total addressable market estimated at $3.8 billion [6][8]. - The assay aims to classify HS patients and guide treatment decisions, potentially improving patient management and outcomes [4][6].